Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer

著录项

• 来源
  《Investigational New Drugs》 |2015年第2期|397-408|共12页
• 作者

  Daniel P. Petrylak; Jitendra G. Gandhi; William R. Clark; Elisabeth Heath; Jianqing Lin; William K. Oh; David B. Agus; Bradley Carthon; Susan Moran; Ning Kong; Ajit Suri; Michael Bargfrede; Glenn Liu;

  展开▼
• 作者单位

  Department of Medicine Smilow Cancer Center Yale University Medical Center">(1);

  Associates in Oncology and Hematology">(2);

  Alaska Clinical Research Center">(3);

  Department of Oncology Karmanos Cancer Institute">(4);

  Department of Medical Oncology Thomas Jefferson University">(5);

  Division of Hematology and Medical Oncology Mount Sinai Hospital">(6);

  Department of Medicine University of Southern California Keck School of Medicine">(7);

  Department of Hematology and Medical Oncology Winship Cancer Institute Emory University">(8);

  Oncology Clinical Research Millennium Pharmaceuticals Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited">(9);

  Biostatistics Millennium Pharmaceuticals Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited">(10);

  Clinical Pharmacology Millennium Pharmaceuticals Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited">(11);

  Clinical Pharmacology Millennium Pharmaceuticals Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited">(11);

  Department of Medicine University of Wisconsin Carbone Cancer Center">(12);

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类
• 关键词

  Genitourinary cancers; Prostate cancer; Phase 1/2 clinical trial; Orteronel; Docetaxel; Prednisone;

  机译：泌尿生殖系统癌症;前列腺癌;1/2期临床试验;Orteronel;多西他赛;强的松;